Huawei is making headlines by testing its new Ascend 910D AI chip, a move aimed at challenging Nvidia’s dominance, particularly with high-end offerings such as the H100. This development could shake up the competitive landscape in the AI chip sector, prompting reactions from major technology players. Alongside this, Merck KGaA announced its acquisition of SpringWorks Therapeutics for $3.9 billion, strengthening its cancer drug portfolio. These significant corporate actions highlight the dynamic nature of the tech and pharmaceutical industries as they adapt and evolve.